# Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly

> **NCT01412424** · PHASE3 · COMPLETED · sponsor: **Chiasma, Inc.** · enrollment: 155 (actual)

## Conditions studied

- Acromegaly

## Interventions

- **DRUG:** Octreotide capsules

## Key facts

- **NCT ID:** NCT01412424
- **Lead sponsor:** Chiasma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2017-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01412424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01412424, "Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01412424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*